People: PDL BioPharma Inc (PDLI.O)

PDLI.O on Nasdaq

8.37USD
24 May 2013
Price Change (% chg)

$0.02 (+0.24%)
Prev Close
$8.35
Open
$8.34
Day's High
$8.41
Day's Low
$8.29
Volume
1,187,724
Avg. Vol
1,792,209
52-wk High
$8.48
52-wk Low
$6.18

Search Stocks

Summary

Name Age Since Current Position

John McLaughlin

 61 2013 President, Chief Executive Officer, Director

Peter Garcia

 52 2013 Chief Financial Officer, Acting Chief Accounting Officer, Vice President

Christopher Stone

 47 2009 Vice President, General Counsel, Secretary

Danny Hart

 36 2012 Deputy General Counsel, Assistant Secretary

Jody Lindell

 61 2009 Independent Director

Paul Sandman

 64 2008 Independent Director

Harold Selick

 57 2009 Independent Director
» Insider Trading

Biographies

Name Description

John McLaughlin

 Mr. John P. McLaughlin is President, Chief Executive Officer, Director of PDL BioPharma Inc. He is no longer Acting Chief Financial Officer, Acting Chief Accounting Officer of the Company effective May 13, 2013. He was elected a director of the Company in October 2008. Mr. McLaughlin has been President and Chief Executive Officer since December 18, 2008, when the Company spun-off Facet Biotech Corporation. In addition to his role as President and Chief Executive Officer, Mr. McLaughlin currently serves as Acting Chief Financial Officer. From November 6, 2008, until the spin-off, he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr. McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc., and co-founded and served as a director of Peak Surgical, Inc., a private medical device company, until it was acquired by Medtronic in 2011. Mr. McLaughlin currently serves as a director of Seattle Genetics, Inc., a publicly-traded biopharmaceutical company. He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America.

Peter Garcia

 Mr. Peter S. Garcia has been appointed as Chief Financial Officer, Acting Chief Accounting Officer, Vice President of PDL BioPharma, Inc., effective May 13, 2013. Mr. Garcia brings more than 25 years of financial management experience to the position. From October 2011 until joining PDL, Mr. Garcia served as Chief Financial Officer of BioTime, Inc., a publicly traded biotechnology company, where he was responsible for global financial operations, including accounting, financial planning, investor relations, mergers and acquisitions and risk management. From 2009 to 2011, Mr. Garcia served as Chief Financial Officer and Secretary of Marina Biotech, Inc., a publicly traded biotechnology company. From 2004 to 2008, Mr. Garcia was the Chief Financial Officer of Nanosys Inc. From 2001 to 2004, Mr. Garcia was Chief Financial Officer of Nuvelo Inc., a publicly held biopharmaceutical company. Between 1996 and 2001 Mr. Garcia served as Chief Financial Officer of Novacept, IntraBiotics Pharmaceuticals and Dendreon Corp. From 1990 to1996, he was a financial executive with Amgen Inc. during its early days of commercializing therapeutics. Mr. Garcia graduated from Stanford University in 1983 with a Bachelor of Arts degree in economics and sociology with honors. In 1985, he earned his MBA from the University of California Los Angeles with a concentration in finance and accounting.

Christopher Stone

 Mr. Christopher Lewis Stone, J.D., is Vice President, General Counsel, Secretary of PDL BioPharma, Inc since Febraury 2, 2009 . He brings more than 21 years of legal experience to the role. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection and licensing. Prior to that time, he was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company which was acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications, as well as managed multiple litigation and interference proceedings and numerous European patent oppositions. Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.

Danny Hart

 Mr. Danny Hart is Deputy General Counsel, Assistant Secretary of PDL BioPharma, Inc. He served as Deputy General Counsel and Assistant Secretary, joined the Company in January 2010 as the Company’s Corporate Counsel. Since joining the Company, Mr. Hart was promoted to Associate Corporate Counsel and Assistant Secretary in April 2011 and then to his current position of Deputy General Counsel and Assistant Secretary in January 2012. From 2006 until he joined the Company, Mr. Hart worked as an associate with Hogan & Hartson LLP (now Hogan Lovells US LLP), a international law firm, where his practice focused on securities, corporate governance and mergers and acquisitions. Before joining Hogan & Hartson, Mr. Hart began his legal career at Skadden, Arps, Slate, Meagher & Flom LLP, a leading international law firm, where he focused on corporate restructurings. Mr. Hart received a J.D. from Vanderbilt University Law School and a B.A. from the University of Washington in Seattle.

Jody Lindell

 Ms. Jody S. Lindell is Independent Director of PDL BioPharma, Inc., since March 11, 2009. Ms. Lindell is President and Chief Executive Officer of S.G. Management, Inc., an asset management company she has headed since 2000. Prior to that, Ms. Lindell was a partner with KPMG LLP where she served as Partner-In-Charge of the Industrial Markets and Healthcare and Life Sciences practices for the Western Area. Through September 2007, she served as a director and on the Audit and Director’s Loan Committees for First Republic Bank, which was a publicly-traded financial institution that has since been acquired. Ms. Lindell continues to serve on the Advisory Board and Advisors Loan Committee for First Republic Bank. She has also served as a director of The Cooper Companies since March 2006. She is a Certified Public Accountant (inactive) and holds a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

Paul Sandman

 Mr. Paul W. Sandman is Independent Director of PDL BioPharma Inc., since October 8, 2008. Mr. Sandman served at Boston Scientific Corporation in various management positions from May 1993 to February 2008, most recently as its Executive Vice President, Secretary and General Counsel. From 1984 to April 1993, he served at Wang Laboratories, Inc., most recently as Senior Vice President, General Counsel and Secretary. Mr. Sandman received his A.B. from Boston College and his J.D. from Harvard Law School.

Harold Selick

 Dr. Harold E. Selick, Ph.D., is Independent Director of PDL BioPharma, Inc., since August 3, 2009. From June 2002, Dr. Selick has served as Chief Executive Officer and a director of Threshold Pharmaceuticals, Inc., a publicly-traded biotechnology company. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax, Dr. Selick held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc.), he co-invented technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick currently serves as Chairman of the Board of Directors of Catalyst Biosciences, a privately-held drug discovery and development company, a director of InteKrin Therapeutics, a clinical-stage, privately-held biopharmaceutical company, and a director of Protagonist Therapeutics, a privately-held biotechnology company. Dr. Selick received his B.A. and Ph.D. degrees from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Basic Compensation

Name Fiscal Year Total

John McLaughlin

 1,164,350

Peter Garcia

 --

Christopher Stone

 654,473

Danny Hart

 289,175

Jody Lindell

 --

Paul Sandman

 --

Harold Selick

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

John McLaughlin

 28,415 91,667

Peter Garcia

 0 0

Christopher Stone

 0 0

Danny Hart

 0 0

Jody Lindell

 0 0

Paul Sandman

 0 0

Harold Selick

 0 0

Insider Trading

Name Shares Traded Price

STONE CHRISTOPHER LEWIS

 16,458 $6.72

MCLAUGHLIN JOHN PETER

 29,911 $6.72

HART DANNY J JR

 4,494 $6.72

TOMLINSON BRUCE

 16,509 $6.36

FRANK FREDERICK

 7,924 $6.31

SELICK HAROLD E

 7,924 $6.31

LINDELL JODY S

 7,924 $6.31

SANDMAN PAUL W

 7,924 $6.31

MCLAUGHLIN JOHN PETER

 31,955 $6.29

HART DANNY J JR

 4,801 $6.29

STONE CHRISTOPHER LEWIS

 17,583 $6.29

KRUMEL CAROLINE J

 4,801 $6.29

LINDELL JODY S

 8,489 $5.89

SANDMAN PAUL W

 8,489 $5.89

FRANK FREDERICK

 8,489 $5.89

SELICK HAROLD E

 8,489 $5.89
» Full list on Insider Trading
Search Stocks